Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

Abstract Background Malignant pleural mesothelioma (MPM) is a very rare and highly aggressive cancer of the pleura associated in most cases with asbestos exposure. To date, no really efficient treatments are available for this pathology. Recently, it has been shown that epigenetic drugs, particularl...

Full description

Bibliographic Details
Main Authors: Douae Bensaid, Thibaut Blondy, Sophie Deshayes, Virginie Dehame, Philippe Bertrand, Marc Grégoire, Mohammed Errami, Christophe Blanquart
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Clinical Epigenetics
Subjects:
Malignant pleural mesothelioma
HDAC inhibitors
Decitabine (5-aza-2′-deoxycytidine)
Epigenetic drugs
Immunotherapy
Tumor antigen
Online Access:http://link.springer.com/article/10.1186/s13148-018-0517-9

Internet

http://link.springer.com/article/10.1186/s13148-018-0517-9

Similar Items